Ningbo Menovo Pharmaceutical Co., Ltd.
Simbol: 603538.SS
SHH
14.58
CNYTržna cena danes
-165.8310
Razmerje P/E
-26.5330
Razmerje PEG
3.09B
Kapaciteta MRK
- 0.01%
Donos DIV
Ningbo Menovo Pharmaceutical Co., Ltd. (603538-SS) Finančni izkazi
Bilanca stanja
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 3108.99 | 724.7 | 1009.3 | 793.2 | |||||||||||||
balance-sheet.row.short-term-investments | 961.42 | 268.6 | 217.4 | 371.4 | |||||||||||||
balance-sheet.row.net-receivables | 1197.96 | 320.7 | 231.5 | 266.2 | |||||||||||||
balance-sheet.row.inventory | 2630.14 | 612.6 | 594.4 | 579.7 | |||||||||||||
balance-sheet.row.other-current-assets | 198.07 | 50.3 | 59.2 | 63.4 | |||||||||||||
balance-sheet.row.total-current-assets | 7254.8 | 1759.4 | 1894.4 | 1702.4 | |||||||||||||
balance-sheet.row.property-plant-equipment-net | 7582.87 | 1900.3 | 1801.9 | 1614.7 | |||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 22.7 | |||||||||||||
balance-sheet.row.intangible-assets | 802.34 | 206.2 | 172.5 | 201.7 | |||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 802.34 | 206.2 | 172.5 | 224.4 | |||||||||||||
balance-sheet.row.long-term-investments | 832.39 | 315.3 | 82.7 | -51.8 | |||||||||||||
balance-sheet.row.tax-assets | 335.17 | 42.7 | 123.1 | 33.3 | |||||||||||||
balance-sheet.row.other-non-current-assets | 942.78 | 199.6 | 344.8 | 478.5 | |||||||||||||
balance-sheet.row.total-non-current-assets | 10495.55 | 2664.1 | 2525.1 | 2299.1 | |||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.total-assets | 17750.35 | 4423.5 | 4419.5 | 4001.5 | |||||||||||||
balance-sheet.row.account-payables | 2040.98 | 553.7 | 499.3 | 389.1 | |||||||||||||
balance-sheet.row.short-term-debt | 2165.58 | 542.8 | 497 | 505 | |||||||||||||
balance-sheet.row.tax-payables | 115.34 | 25.5 | 72.1 | 34.6 | |||||||||||||
balance-sheet.row.long-term-debt-total | 3022.3 | 759.6 | 705.6 | 755.3 | |||||||||||||
Deferred Revenue Non Current | 330.02 | 81.5 | 70.6 | 48.7 | |||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 220.86 | - | - | - | |||||||||||||
balance-sheet.row.other-current-liab | 8.2 | 2 | 171 | 3.9 | |||||||||||||
balance-sheet.row.total-non-current-liabilities | 3592.57 | 859.6 | 884 | 876.2 | |||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.capital-lease-obligations | 102.15 | 15.7 | 30.3 | 28 | |||||||||||||
balance-sheet.row.total-liab | 8956.27 | 2237.8 | 2246.2 | 2023 | |||||||||||||
balance-sheet.row.preferred-stock | 72.59 | 36.3 | 0 | 0 | |||||||||||||
balance-sheet.row.common-stock | 853.57 | 213.4 | 213.4 | 151.3 | |||||||||||||
balance-sheet.row.retained-earnings | 4918.84 | 1210.6 | 1234.3 | 937.4 | |||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 986.88 | 75.6 | 101.4 | 77.6 | |||||||||||||
balance-sheet.row.other-total-stockholders-equity | 1595.49 | 560.4 | 535.9 | 585.2 | |||||||||||||
balance-sheet.row.total-stockholders-equity | 8427.36 | 2096.3 | 2085 | 1751.5 | |||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 17750.35 | 4423.5 | 4419.5 | 4001.5 | |||||||||||||
balance-sheet.row.minority-interest | 366.72 | 89.4 | 88.3 | 227 | |||||||||||||
balance-sheet.row.total-equity | 8794.08 | 2185.7 | 2173.2 | 1978.5 | |||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 17750.35 | - | - | - | |||||||||||||
Total Investments | 1259.87 | 315.3 | 300.1 | 319.6 | |||||||||||||
balance-sheet.row.total-debt | 5187.88 | 1302.5 | 1202.6 | 1260.4 | |||||||||||||
balance-sheet.row.net-debt | 3040.31 | 846.4 | 410.7 | 838.6 |
Izkaz denarnih tokov
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -17.82 | 367.6 | 158.1 | 173.1 | ||||||||||||
cash-flows.row.depreciation-and-amortization | 90.3 | 101.8 | 98.9 | 85 | ||||||||||||
cash-flows.row.deferred-income-tax | -13.64 | -40.2 | -21 | 18.4 | ||||||||||||
cash-flows.row.stock-based-compensation | 11.27 | 24.7 | 5.3 | 10.9 | ||||||||||||
cash-flows.row.change-in-working-capital | -124.06 | -85.4 | -62.2 | -2.8 | ||||||||||||
cash-flows.row.account-receivables | -98.84 | -213.6 | -50.9 | -28.2 | ||||||||||||
cash-flows.row.inventory | -49.56 | -183 | -124.7 | -83 | ||||||||||||
cash-flows.row.account-payables | 0 | 351.4 | 134.4 | 63.3 | ||||||||||||
cash-flows.row.other-working-capital | 24.33 | -40.2 | -21 | 45.1 | ||||||||||||
cash-flows.row.other-non-cash-items | 36.58 | -91.4 | 41.5 | -32.9 | ||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -28.65 | 0 | 0 | 0 | ||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -142.43 | -571.6 | -529.9 | -311.7 | ||||||||||||
cash-flows.row.acquisitions-net | 0.3 | 487.9 | -47.1 | 0.5 | ||||||||||||
cash-flows.row.purchases-of-investments | -994.74 | -713.9 | -1640.5 | -865 | ||||||||||||
cash-flows.row.sales-maturities-of-investments | 853.67 | 902.5 | 1562.2 | 693.5 | ||||||||||||
cash-flows.row.other-investing-activites | -116.67 | -54.6 | 52 | 3.8 | ||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -247.84 | 50.3 | -603.3 | -479 | ||||||||||||
cash-flows.row.debt-repayment | -399.52 | -749.5 | -788.1 | -802.5 | ||||||||||||
cash-flows.row.common-stock-issued | 0 | 0.1 | 0.2 | 0.5 | ||||||||||||
cash-flows.row.common-stock-repurchased | 0 | -0.1 | -0.2 | -0.5 | ||||||||||||
cash-flows.row.dividends-paid | -60.49 | -50 | -13.8 | -41 | ||||||||||||
cash-flows.row.other-financing-activites | 446.21 | 621.1 | 1385.1 | 981.9 | ||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 60.68 | -178.5 | 583.1 | 138.4 | ||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | -22.05 | 14.6 | -2.3 | -2 | ||||||||||||
cash-flows.row.net-change-in-cash | -237.86 | 163.4 | 198.2 | -91 | ||||||||||||
cash-flows.row.cash-at-end-of-period | 1234.49 | 537 | 373.6 | 174.5 | ||||||||||||
cash-flows.row.cash-at-beginning-of-period | 1472.34 | 373.6 | 175.4 | 265.5 | ||||||||||||
cash-flows.row.operating-cash-flow | -28.65 | 277 | 220.6 | 251.6 | ||||||||||||
cash-flows.row.capital-expenditure | -142.43 | -571.6 | -529.9 | -311.7 | ||||||||||||
cash-flows.row.free-cash-flow | -171.08 | -294.7 | -309.3 | -60.1 |
Vrstica izkaza poslovnega izida
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 1232.95 | 1216.5 | 1457 | 1258.1 | |||||||||||||
income-statement-row.row.cost-of-revenue | 839.39 | 840.9 | 872.8 | 788.9 | |||||||||||||
income-statement-row.row.gross-profit | 393.56 | 375.6 | 584.2 | 469.2 | |||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||
income-statement-row.row.research-development | 99.54 | - | - | - | |||||||||||||
income-statement-row.row.selling-general-administrative | 57.01 | - | - | - | |||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 52.13 | - | - | - | |||||||||||||
income-statement-row.row.other-expenses | -11.95 | -10.8 | 116.4 | 110.8 | |||||||||||||
income-statement-row.row.operating-expenses | 305.9 | 291.2 | 341.4 | 281 | |||||||||||||
income-statement-row.row.cost-and-expenses | 1145.29 | 1132.1 | 1214.2 | 1069.9 | |||||||||||||
income-statement-row.row.interest-income | 6.12 | 5.5 | 5.7 | 2.2 | |||||||||||||
income-statement-row.row.interest-expense | 30.96 | 29.1 | 27.4 | 27.2 | |||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 52.13 | - | - | - | |||||||||||||
income-statement-row.row.total-other-income-expensenet | -77.38 | -76.4 | -21.2 | -7.6 | |||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||
income-statement-row.row.other-operating-expenses | -11.95 | -10.8 | 116.4 | 110.8 | |||||||||||||
income-statement-row.row.total-operating-expenses | -77.38 | -76.4 | -21.2 | -7.6 | |||||||||||||
income-statement-row.row.interest-expense | 30.96 | 29.1 | 27.4 | 27.2 | |||||||||||||
income-statement-row.row.depreciation-and-amortization | 125.92 | 118.5 | 128.3 | 124.1 | |||||||||||||
income-statement-row.row.ebitda-caps | 59.17 | - | - | - | |||||||||||||
income-statement-row.row.operating-income | -15.63 | 18.7 | 405.3 | 187.9 | |||||||||||||
income-statement-row.row.income-before-tax | -27.57 | 8 | 384.2 | 180.3 | |||||||||||||
income-statement-row.row.income-tax-expense | -13.31 | -8.2 | 16.5 | 22.2 | |||||||||||||
income-statement-row.row.net-income | -17.82 | 11.6 | 338.9 | 142.5 |
Pogosto zastavljeno vprašanje
Kaj je Ningbo Menovo Pharmaceutical Co., Ltd. (603538.SS) skupna sredstva?
Ningbo Menovo Pharmaceutical Co., Ltd. (603538.SS) skupna sredstva so 4423515920.000.
Kakšen je letni prihodek podjetja?
Letni prihodki so 550731997.000.
Kolikšna je stopnja dobička podjetja?
Dobiček podjetja je 0.319.
Kakšen je prosti denarni tok podjetja?
Prosti denarni tok je -0.853.
Kolikšna je neto stopnja dobička podjetja?
Čista stopnja dobička je -0.014.
Kolikšni so skupni prihodki podjetja?
Celotni prihodki so -0.013.
Kaj je Ningbo Menovo Pharmaceutical Co., Ltd. (603538.SS) čisti dobiček (čisti dobiček)?
Čisti dobiček (čisti prihodek) je 11585592.000.
Kolikšen je skupni dolg podjetja?
Skupni dolg je 1302458461.000.
Kolikšni so stroški poslovanja?
Stroški poslovanja so 291175048.000.
Kolikšno je število denarnih sredstev podjetja?
Denarna sredstva podjetja so 351891745.000.